首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays
【24h】

C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays

机译:C8-取代的吡啶吡喃-4(3H) - 酮:探索效率的鉴定,细胞渗透剂Jumonji C结构域含有组蛋白赖氨酸脱甲基酶4亚家族(KDM4)抑制剂,在基于细胞的靶标中的化合物分析 订婚分析

获取原文
获取原文并翻译 | 示例
           

摘要

Residues in the histone substrate binding sites that differ between the.KDM4 and KDM5 subfamilies were identified. Subsequently, a C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one series was designed to rationally exploit these residue differences between the histone substrate binding sites in order to improve affinity for the KDM4-subfamily over KDM5-subfamily enzymes. In particular, residues E169 and V313 (KDM4A numbering) were targeted. Additionally, conformational restriction of the flexible pyridopyrimidinone C8-substituent was investigated. These approaches yielded potent and cell-penetrant dual KDM4/5-subfamily inhibitors including 19a (KDM4A and KDM5B Ki = 0.004 and 0.007 mu M, respectively). Compound cellular profiling in two orthogonal target engagement assays revealed a significant reduction from biochemical to cell-based activity across multiple analogues; this decrease was shown to be consistent with 20G competition, and suggests that sub-nanomolar biochemical potency will be required with C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one compounds to achieve sub-micromolar target inhibition in cells. (C) 2019 The Authors. Published by Elsevier Masson SAS.
机译:鉴定了在kdm4和Kdm5亚壳之间不同之间不同的组蛋白底物结合位点的残留物。随后,设计了C8取代的吡啶-4(3H) - ONE系列以合理地利用这些残留物在组蛋白底物结合位点之间的残留差异,以改善对KDM4-亚家族的亲和力在KDM5上亚家族酶。特别地,靶向残留物E169和V313(KDM4A编号)。另外,研究了柔性吡啶嘧啶酮C8取代基的构象限制。这些方法产生有效性和细胞渗透剂双KDM4 / 5-亚家族抑制剂,包括19a(KDM4a和KDM5B ki = 0.004和0.007μm)。两种正交靶接合测定中的复合细胞分析显示,从多个类似物的生化到基于细胞的活性显着降低;该降低显示与20g竞争一致,表明C8取代的吡啶[3,4-D]嘧啶-4(3H)化合物将需要亚纳米摩尔生物化学效力,以实现亚微摩尔靶抑制在细胞中。 (c)2019年作者。由Elsevier Masson SA出版。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号